Bone Markers Measured During and After Short Steroid Treatment in Joint Inflammation
Studies how bone turnover markers change in adults with inflammatory joint disease taking steroids briefly.
Plain-language title generated from the registry record
Registry title: Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease
Key facts
- Where
- Drammen and Oslo, NorwaySee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 25 to 90 with an inflammatory rheumatic joint disease who are starting disease-modifying treatment, or who are on stable DMARD treatment and get a glucocorticoid injection.
- Age
- 25 to 90 years
- Sex
- Women and men can join.
- Disease stage
- Inflammatory rheumatic joint disease.
- Earlier treatment
- Either starting disease-modifying treatment, with or without glucocorticoids, or on stable DMARD treatment with a glucocorticoid injection. No long-term glucocorticoid treatment, and no glucocorticoid treatment in the last year before joining.
Main reasons for not taking part
- Known osteoporosis or osteoporosis treatment
- Any fracture within the last year
- Oestrogen treatment
- Active cancer
- Kidney failure
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 90 years old?
Source: NCT06395883, who can take part
Where in Norway
- Vestre Viken HF, DrammenDrammen, NorwayContact: Birgitte Nellemann Nellemann, MD PHDTaking people
- Diakonhjemmet HospitalOslo, NorwayContact: Birgitte Nellemann Nellemann, MD PHDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Diakonhjemmet Hospital
- Trial code
- NCT06395883
- Record updated
- 19 August 2026
- Original description
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment.Read full original descriptionShow less
Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease - the BOOGIE Study
Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment.
There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
Inclusion: diagnosis of inflammatory rheumatic joint disease; indication of disease modifying treatment initiation with or without glucocorticoids OR; stable DMARD treatment with parenteral glucocorticoid injection.
Exclusion: glucocorticoid treatment within the last year prior to inclusion; active cancer; kidney failure; known osteoporosis or osteoporosis treatment; women during the transitory phase; oestrogen treatment; any fracture within the last year; chronic glucocorticoid treatment.